This finding contrasts with the situation in human GB and WHO CNS Grade 4 astrocytoma, where homozygous deletion of CDKN2A is a hallmark alteration associated with high proliferative activity and poor prognosis [69]. Here, CDKN2A is linked to astrocytoma (excluding glioblastoma).